Phosphatidylinositol 4-kinase 2 alpha (PI4KA) inhibitors have been used as cancer therapeutic agents in only a few studies, having demonstrated good results as a radiosensitizing agent.110 Co-targeting PI4KA simultaneously with PD-L1/PD-1 blockade could be an attractive approach to reinforce the cytotoxicity of PD-L1 blockade therapies over cancer cells. This evidence concerns the gene CD274 and cancer.